Evidence map›Paper›PMID 39813173›Full record

ArticleActa oncologica (Stockholm, Sweden)2025

Distinct patterns of osteoradionecrosis after photon-based radiotherapy and carbon ion radiotherapy for unresectable adenoid cystic carcinoma of the head and neck: case series from two institutions.

Eivind Storaas, Marta D Switlyk, Sigrun Dahl, Cecilie D Amdal, Åse Bratland, Thuy-Tien M Huynh, Hanne A Eide, Barbara Vischioni, Ester Orlandi, Einar Dale

Abstract readMulticenter Study
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eivind StoraasDepartment of Oncology, Oslo University Hospital, Norway.ORCID 0000-0001-6330-3074
Marta D SwitlykDepartment of Radiology and Nuclear Medicine, Oslo University Hospital, Norway.ORCID 0000-0003-1246-6556
Sigrun DahlDepartment of Oncology, Oslo University Hospital, Norway.ORCID 0000-0002-9641-4640
Cecilie D AmdalDepartment of Oncology, Oslo University Hospital, Norway.ORCID 0000-0001-8422-8085
Åse BratlandDepartment of Oncology, Oslo University Hospital, Norway.ORCID 0009-0009-9789-7961
Thuy-Tien M HuynhDepartment of Oncology, Oslo University Hospital, Norway; Faculty of Medicine, University of Oslo, Norway.ORCID 0000-0003-0433-6065
Hanne A EideDepartment of Oncology, Oslo University Hospital, Norway.ORCID 0000-0002-9095-1883
Barbara VischioniCentro Nazionale di Adroterapia Oncologica, Pavia, Italy.ORCID 0000-0003-4920-2239
Ester OrlandiClinical Department, National Center for Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy; Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy.ORCID 0000-0001-6495-8574
Einar DaleDepartment of Oncology, Oslo University Hospital, Norway. eindal@ous-hf.no.ORCID 0000-0001-9483-2788

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeTo present the clinical outcomes of two series of patients treated with carbon-ion radiotherapy (CIRT) and definitive photon radiotherapy (RT) for adenoid cystic carcinoma of the head and neck (HN-ACC). MATERIAL AND

methodsThe first cohort of six patients was referred from Oslo University Hospital (OUS) to Centro Nazionale di Adroterapia Oncologica (CNAO, Pavia, Italy) for CIRT in 2014-2017. The second cohort included 18 patients treated with definitive photon RT at OUS in 2005-2017. The primary endpoint was an evaluation of osteoradionecrosis (ORN) in the two cohorts. The secondary endpoints were treatment efficacy by local control (LC), progression-free survival (PFS), and overall survival (OS).

resultsThe tumor stage was T4 for all the patients in the CIRT group and 15 (84%) in the photon group. There were three (50%) patients with grade 3 ORN in the CIRT group compared to one (6%) with grade 3 ORN in the photon group (p = 0.05). The 5-year LC (95% CI), PFS, and OS rates in the CIRT group and the photon group were 33% (11-100) and 39% (19-76), 17% (9-100) and 23% (2-59), and 80% (52-100) and 50% (31-82), respectively.

interpretationHalf of the patients in the CIRT cohort experienced ORN requiring surgical management during the follow-up. Patients with ACC referred for CIRT often have a worse prognosis and more advanced disease than patients treated with photons. When returning from the referring center, these patients need close follow-up often in collaboration with treating centers to manage toxicity that impacts quality of life.

Indexed as

Carcinoma, Adenoid CysticHead and Neck NeoplasmsHeavy Ion RadiotherapyOsteoradionecrosisPhotonsAdultAgedFemaleHumansMaleMiddle AgedRetrospective Studies

Identifiers

PMID39813173
PMCPMC11758679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.